查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143404

肽類藥物偶聯物市場：依產品、類型、疾病、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Peptide Drug Conjugates Market, By Product, By Type, By Disease, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 321 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，胜肽類藥物偶聯物市場價值將達到 52.801 億美元，並預計從 2026 年到 2033 年以 11.9% 的複合年成長率成長。

胜肽-藥物偶聯物（PDCs）是一種標靶治療方法，它將具有藥理活性的藥物與胜肽載體透過可裂解或不可裂解的連接子連接起來。胜肽-藥物偶聯物的概念是基於目標胜肽（其與目標細胞或組織表面特定受體相互作用的能力）、待遞送的藥物分子以及連接藥物分子和胜肽分子的連接子。與用於治療腫瘤、代謝性疾病和罕見疾病的動脈解毒細胞（ADCs）相比，PDCs具有許多優勢。

肽類藥物複合物市場－市場動態

癌症治療需求的成長正在加速市場成長。

癌症治療需求的不斷成長推動了肽-藥物偶聯物（DP-DM）的應用。這是因為DP-DM能夠透過標靶給藥、提高特異性和減少副作用來增強治療效果，從而改善癌症患者的醫療保健品質。例如，根據美國國立衛生研究院（NIH）網站截至2026年1月的數據，2020年1月至2025年1月期間，歐盟腫瘤領域共收到60份上市許可申請（MAA），每年獲準12份。在研究期間收到的59份申請中，全部獲得正面評價，其中28份（47%）用於血液腫瘤，10份（17%）用於肺癌，6份（10%）用於乳癌。此外，研究也發現，約50%的申請為生物技術產品，31%為單株抗體。這些趨勢預計將促進DP-DM在癌症治療和研發領域的應用。

胜肽-藥物偶聯物市場—市場細分分析：

全球胜肽類藥物偶聯物市場按產品類型、類別、疾病和地區進行細分。

Pluvicto是一種利用放射性配體療法治療進行性前列腺癌的藥物，在胜肽類藥物偶聯物市場佔據重要佔有率。 2025年3月，諾華公司正式獲得美國FDA批准，Pluvicto（鎦-177維匹伏肽四氫西坦）可作為第一線治療藥物，用於治療PSMA陽性轉移性前列腺癌，且無需化療。此次獲準預計將使合格的患者數量增加，從而使銷售額成長兩倍。適應症的擴大有望促進Pluvicto的普及，並推動諾華公司的發展。

肽類藥物複合物市場—區域分析

由於癌症和慢性病發病率不斷上升，以及標靶治療的日益普及，北美在胜肽類藥物偶聯物市場佔據重要地位。例如，根據美國疾病管制與預防中心（CDC）的數據，截至2026年6月，美國年齡已調整的的癌症新病例率為每10萬人453.4例。其中，都市區為每10萬人450.9例，農村地區為每10萬人466.6例。男性癌症發生率為每10萬人490.4例，女性為每10萬人428.9例。這很可能將推動該地區對靶向肽類癌症療法的需求。

歐洲肽類藥物偶聯物市場預計將受益於其強大的臨床研究能力和政府促進生物技術創新的政策而蓬勃發展。例如，根據歐盟委員會2026年9月發布的CORDIS報告，生物技術每年將為歐盟經濟貢獻近400億歐元，其中超過80%來自醫療生物技術。此外，過去十年，歐洲生物技術產業的成長率是整體經濟成長率的兩倍。

歐洲正透過「地平線歐洲」舉措推動生物技術領域的創新，該計畫旨在促進醫療保健、農業、食品、能源、工業生產、化學品、材料和環境等領域的研究與創新合作。此外，歐盟委員會於2025年12月提出了《歐洲生物技術法案》，以增強該地區生物技術領域的競爭力。這些措施可望加速該地區肽-藥物偶聯物的研發和商業化。

目錄

第1章：胜肽類藥物偶聯物市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：胜肽類藥物偶聯物的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：胜肽類藥物偶聯物產業的分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：胜肽類藥物偶聯物市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：胜肽類藥物偶聯物市場現狀

  • 肽類藥物偶聯物市場佔有率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：胜肽類藥物偶聯物市場：依產品分類

  • 概述
    • 基於細分市場的市佔率分析：按產品
    • OctreoScan
    • Lutathera
    • Pluvicto
    • Illuccix
    • 其他

第8章：胜肽類藥物偶聯物市場：按類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按類型
    • 治療
    • 診斷

第9章：胜肽類藥物偶聯物市場：依疾病分類

  • 概述
    • 基於細分市場的市佔率分析：依疾病分類
    • 胃腸道和胰臟神經內分泌腫瘤（GEP-NETs）
    • 多發性骨髓瘤
    • 其他

第10章：胜肽類藥物偶聯物市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第11章：主要供應商分析：胜肽類藥物偶聯物產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Novartis AG
    • AstraZeneca PLC
    • Oncopeptides AB
    • Bicycle Therapeutics plc
    • Cybrexa Therapeutics, Inc.
    • Angiochem Inc.
    • Soricimed Biopharma Inc.
    • Theratechnologies Inc.
    • PeptiDream Inc.
    • Curium US LLC
    • ProteinQure Inc.
    • Protagonist Therapeutics, Inc.
    • PepGen Corporation
    • Italfarmaco SpA
    • Zealand Pharma A/S
    • BioNTech SE
    • Others

第12章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7594

Peptide Drug Conjugates market size was valued at US$ 5,280.1 Million in 2025, expanding at a CAGR of 11.9% from 2026 to 2033.

Peptide Drug Conjugates (PDCs) are considered one of the forms of targeted therapy that involves conjugation of a pharmacologically active drug with a peptide carrier through a cleavable or non-cleavable linker. The concept of peptide drug conjugate is based on the targeting peptide (ability to interact with a specific receptor located on the surface of the target cell or tissue), the drug molecule that should be delivered and linkers coupling the drug and peptide molecules. The PDCs possess a number of advantages over the ADCs that could be used in oncology and metabolic and rare diseases.

Peptide Drug Conjugates Market- Market Dynamics

Rising Demand for Oncology Therapeutics To Accelerate Market Growth

The rising demand for oncology therapeutics is driving the utilisation of peptide drug conjugates because of their targeted drug delivery, improved specificity, and increased therapeutic efficacy through reduced side effects, improving the quality of healthcare for oncology patients. For example, in January 2026, according to NIH.gov, there were 60 oncology Marketing Authorisation Applications (MAAs) in the EU from January 2020 to January 2025, where 12 are being approved each year, and out of the 59 applications (in the study period), 59 had a positive opinion, in which 28 (47%) are blood cancers, 10 (17%) are lung cancers, and 6 (10%) are breast cancers. The study further reveals that around 50% of applications are biotech products, and 31% are monoclonal antibodies. These trends are expected to support peptide drug conjugate adoption in oncology treatment and development.

Peptide Drug Conjugates Market- Segmentation Analysis:

The Global Peptide Drug Conjugates market is segmented on the basis of Product, Type, Disease, and Region.

Pluvicto holds a significant share in the peptide drug conjugate because of the drug as a means for treating advanced cases of prostate cancer using radioligand therapy. In March 2025, Novartis was the quality FDA approval in the US for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the treatment of PSMA-positive metastatic prostate cancer, as a first-line treatment prior to chemotherapy. This approval will drive up the drug sales threefold due to the number of eligible patients increasing. This expanded approval is expected to increase Pluvicto adoption and support its manufacturers' growth.

Peptide Drug Conjugates Market- Geographical Insights

North America holds a notable position in the Peptide Drug Conjugates market because of the increase in the occurrence of cancer and chronic diseases as well as the increased uptake of targeted treatment. For instance, in June 2026, according to the U.S. Centers for Disease Control and Prevention (Gov), the age-adjusted rate of newly diagnosed cancers in the USA was 453.4 cases per 100,000 people. In urban areas, it was 450.9 per 100,000 people, while in rural regions, it was 466.6 cases of cancer per 100,000 people. Among men, it was 490.4 per 100,000 people, while among women, it was 428.9 cases per 100,000 people. This will propel the demand for targeted peptide-based cancer treatment in the region.

Europe's Peptide Drug Conjugates market will get support due to its high clinical research strength and government policies to encourage innovations in biotechnology. For instance, in September 2026, according to the European Commission's CORDIS, biotechnology adds up to close to EUR 40 billion each year to the European Union economy, where more than 80% comes from health biotechnology. Furthermore, there has been a double growth rate in the biotechnology industry in Europe in the past ten years compared to the economy overall.

The innovation in the biotechnology sector is being encouraged through Europe with the help of its Horizon Europe initiative, wherein collaboration in research and innovation in health, agriculture, food, energy, industrial production, chemistry, materials, and the environment is being promoted. In addition, the European Commission had put forward the concept of the European Biotech Act in December 2025 to enhance the competitiveness of the biotechnology sector within the region. These initiatives are expected to propel peptide drug conjugate research, development, and commercialization in the region.

Peptide Drug Conjugates Market- Competitive Landscape:

Some of the key participants in the Peptide Drug Conjugates market include Bicycle Therapeutics plc, Oncopeptides AB, Theratechnologies Inc., Cybrexa Therapeutics, and Angiochem Inc. The growth in the market is supported by developments in targeted drug delivery, peptide-linker technology, and increasing use of PDCs for the treatment of various diseases, including oncology. In June 2026, Oncopeptides AB started conducting research using OP-701 (INSULA) on patients with glioblastoma, which was the first time when its patented Peptide Drug Conjugate (PDC) platform was subjected to examination in glioblastoma following its success in multiple myeloma. Therefore, advancement in peptide drug conjugate platforms is contributing towards improvements in targeted therapy and oncology.

Recent Developments:

In July 2025, Theratechnologies Inc. announced that the company has signed a definitive agreement to be acquired by CB Biotechnology, LLC, a subsidiary of Future Pak, at a consideration of approximately US$254 million, including contingent value rights, to develop further its portfolio of peptide-drug conjugates (PDC) with su-docetaxel zendusortide (TH1902).

In March 2025, Cybrexa Therapeutics announced new preclinical data for its alphalex(TM) peptide-drug conjugates with tumor-selective targeting and anticancer activity supporting the further development of its pipeline of peptide-drug conjugates (PDC).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PEPTIDE DRUG CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • AstraZeneca PLC
  • Oncopeptides AB
  • Bicycle Therapeutics plc
  • Cybrexa Therapeutics, Inc.
  • Angiochem Inc.
  • Soricimed Biopharma Inc.
  • Theratechnologies Inc.
  • PeptiDream Inc.
  • Curium US LLC
  • ProteinQure Inc.
  • Protagonist Therapeutics, Inc.
  • PepGen Corporation
  • Italfarmaco S.p.A.
  • Zealand Pharma A/S
  • BioNTech SE
  • Others

GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033

  • OctreoScan
  • Lutathera
  • Pluvicto
  • Illuccix
  • Others

GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033

  • Therapeutic
  • Diagnostic

GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033

  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  • Multiple Myeloma
  • Others

GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Peptide Drug Conjugates Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Peptide Drug Conjugates Market Snippet by Product
    • 2.1.2. Peptide Drug Conjugates Market Snippet by Type
    • 2.1.3. Peptide Drug Conjugates Market Snippet by Disease
    • 2.1.4. Peptide Drug Conjugates Market Snippet by Country
    • 2.1.5. Peptide Drug Conjugates Market Snippet by Region
  • 2.2. Competitive Insights

3. Peptide Drug Conjugates Key Market Trends

  • 3.1. Peptide Drug Conjugates Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Peptide Drug Conjugates Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Peptide Drug Conjugates Market Opportunities
  • 3.4. Peptide Drug Conjugates Market Future Trends

4. Peptide Drug Conjugates Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Peptide Drug Conjugates Market : Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Peptide Drug Conjugates Market Landscape

  • 6.1. Peptide Drug Conjugates Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Peptide Drug Conjugates Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
    • 7.1.2. OctreoScan
    • 7.1.3. Lutathera
    • 7.1.4. Pluvicto
    • 7.1.5. Illuccix
    • 7.1.6. Others

8. Peptide Drug Conjugates Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
    • 8.1.2. Therapeutic
    • 8.1.3. Diagnostic

9. Peptide Drug Conjugates Market - By Disease

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Disease, 2025 & 2033 (%)
    • 9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    • 9.1.3. Multiple Myeloma
    • 9.1.4. Others

10. Peptide Drug Conjugates Market - By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Peptide Drug Conjugates Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Peptide Drug Conjugates Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.16. Denmark
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.16.3. Denmark Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.16.4. Denmark Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.16.5. Denmark Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.3.17. Rest of Europe
      • 10.3.17.1. Overview
      • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.3.17.5. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Peptide Drug Conjugates Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.15. Taiwan
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.15.3. Taiwan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.15.4. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.15.5. Taiwan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.16. Vietnam
      • 10.4.16.1. Overview
      • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.16.3. Vietnam Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.16.4. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.16.5. Vietnam Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.4.17. Rest of APAC
      • 10.4.17.1. Overview
      • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.17.3. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.4.17.5. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Peptide Drug Conjugates Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Peptide Drug Conjugates Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.13. Iran
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.13.3. Iran Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.13.4. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.13.5. Iran Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.14. Qatar
      • 10.6.14.1. Overview
      • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.14.3. Qatar Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.14.4. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.14.5. Qatar Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 10.6.15. Rest of MEA
      • 10.6.15.1. Overview
      • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.15.3. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 10.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 10.6.15.5. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Peptide Drug Conjugates Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
    • 11.2.2. AstraZeneca PLC
    • 11.2.3. Oncopeptides AB
    • 11.2.4. Bicycle Therapeutics plc
    • 11.2.5. Cybrexa Therapeutics, Inc.
    • 11.2.6. Angiochem Inc.
    • 11.2.7. Soricimed Biopharma Inc.
    • 11.2.8. Theratechnologies Inc.
    • 11.2.9. PeptiDream Inc.
    • 11.2.10. Curium US LLC
    • 11.2.11. ProteinQure Inc.
    • 11.2.12. Protagonist Therapeutics, Inc.
    • 11.2.13. PepGen Corporation
    • 11.2.14. Italfarmaco S.p.A.
    • 11.2.15. Zealand Pharma A/S
    • 11.2.16. BioNTech SE
    • 11.2.17. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us